Japan’s tooth-regrowth drug passes its first safety test. See how this breakthrough could change dental care by 2030.
HOUSTON--(BUSINESS WIRE)--Saranas, Inc. announced today the compelling results of SAFE-MCS, a multi-center clinical study evaluating the safety of complex high-risk percutaneous coronary intervention ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results